Introduction
============

Prompt identification and treatment of adults newly infected with HIV-1 can dramatically reduce onward transmission and improve the health of the infected individual \[[@R1]\]. Identifying adults with acute HIV-1 infection (AHI), a substantial portion of whom seek urgent care even in resource-constrained settings \[[@R2]\], therefore has tremendous public health importance \[[@R3]\]. Unfortunately, AHI detection has not been emphasized in Sub-Saharan Africa (sSA), where the epidemic burden is greatest \[[@R4],[@R5]\].

Across sSA, AHI symptom prevalence has varied considerably, with higher estimates reported in Kenya \[[@R6]\] than in Uganda \[[@R7]\] and Zambia \[[@R8]\]. Symptoms develop approximately 2 weeks after HIV-1 acquisition, just before plasma viral load peaks \[[@R9],[@R10]\], and the number of symptoms correlates with higher plasma viral load before seroconversion \[[@R11]\]. Thus, strategies aiming to diagnose symptomatic AHI patients at care seeking may identify those with more severe symptoms and higher peak \[[@R11]\] and set point \[[@R9],[@R12]\] viral load.

Although infection with HIV-1 subtypes C or D (vs. subtype A) has predicted faster progression to AIDS and death in several studies in Africa \[[@R12]--[@R15]\], little systematic research has been conducted on the clinical manifestations of AHI in relation to subtype. As substantial geographical differences in ARS have been documented in sSA \[[@R2],[@R6]--[@R8]\] and HIV-1 subtype varies geographically, we hypothesized that the occurrence of symptoms around the time of seroconversion could be correlated with HIV-1 subtype. We sought to test this hypothesis in the largest seroconverter cohort study from Africa, a research collaboration of nine clinical research centres (CRC), representing countries with predominant HIV-1 subtypes A, C, or D \[[@R16]\].

Methods
=======

Study design and procedures
---------------------------

Data derived from 'protocol C' of the International AIDS Vaccine Initiative (IAVI), a multicentre early HIV infection cohort study \[[@R15]\]. As described previously \[[@R16]\], adults at risk of HIV-1 were enrolled into a prospective cohort study across CRCs in Kenya, Uganda, Rwanda, Zambia, and South Africa. These HIV incidence cohorts included predominantly: cohabiting heterosexual partners of an HIV infected, antiretroviral therapy-naïve person (Zambia; Rwanda; Uganda); sex workers and their clients, or clients with a sexually transmitted infection (Kenya); MSM (Kenya and Rustenburg, South Africa); or adolescents (Cape Town). Incidence study volunteers were tested for HIV-1 monthly or quarterly (depending on site) as described previously \[[@R17],[@R18]\].

Volunteers with incident HIV infection were invited to enrol into protocol C between February 2006 and December 2011. At enrolment, all patients completed a standardized questionnaire asking whether they had experienced symptoms consistent with acute retroviral syndrome (ARS) in the past 90 days: fever, headache, myalgia/arthralgia, fatigue, anorexia, pharyngitis, diarrhoea, night sweats, skin rash, lymphadenopathy, oral ulcers, or 'other'. Enrolment viral load \[[@R16]\] was measured and HIV-1 subtype was determined by sequencing the *POL* (HIV-1 genome) region \[[@R19]\].

The ethical review boards of all participating CRCs approved the study protocol and all study volunteers provided written informed consent.

Estimated date of infection and timing of symptom ascertainment
---------------------------------------------------------------

The estimated date of HIV-1 infection (EDI) was determined as follows \[[@R20]\]: 10 days before the sample collection date when the sample had a positive RNA viral load, negative p24 antigen and negative HIV-1 serology; 14 days before a positive p24 antigen test (regardless of RNA result) with negative HIV-1 serology; 19 days before the date that rapid HIV-1 antibody tests were discordant (regardless of p24 antigen or RNA result); or the mid-term date between a previously negative and subsequently fully positive HIV-1 serologic test (two rapid tests conducted in parallel) \[[@R2]\].

To limit recall error and maximize questionnaire sensitivity, we restricted the current analysis to patients who enrolled in protocol C within 6 weeks of EDI \[[@R15]\], based on our earlier finding that reported symptom prevalence was considerably lower in patients evaluated more than 6 weeks vs. within 6 weeks after EDI \[[@R21]\].

Data analysis
-------------

We first calculated descriptive statistics, including prevalence of each ARS symptom and prevalence of 'any' symptom by HIV-1 subtype. We then used two sets of multivariable log-binomial regression models to estimate the association between HIV-1 subtype and reporting any ARS symptom. In one set, we included enrolment log~10~ viral load to estimate the direct effect (i.e. not mediated through viral load) of subtype on ARS symptoms; in the other, we excluded viral load to estimate the total effect of subtype. In both sets, we started with a full model containing two potential confounders -- sex and time between EDI and enrolment -- that have been reported as being associated with ARS symptoms \[[@R21],[@R22]\] and were associated with subtype in our study (because of differences in population types and enrolment timing across sites). To maximize precision, we dichotomized the exposure in each set of models as subtype A vs. subtype C or D (combined) after we observed that symptom prevalence and other characteristics were similar for subtypes C and D (Supplemental Figure S1, Supplemental Table S1). We used backward selection with α = 0.05 to sequentially remove variables and arrive at a final model within each set.

To explore the possibility that differences in reported symptoms across subtypes might be because of differential symptom reporting/ascertainment and/or unmeasured confounding across study centres, we conducted a sensitivity analysis of ARS symptoms by subtype only among volunteers at the two centres (Masaka and Kilifi), where cases across the three subtypes were enrolled. Multivariable analyses were not possible in this subset. Additionally, we examined univariable associations between 37 common human leucocyte antigen (HLA) variants (see Supplemental List S1) and ARS symptom reporting (any vs. none) to determine (accounting for multiple comparisons) whether adjustment for any of these HLA types was needed. We performed a similar analysis to assess whether calendar year of enrolment was associated with ARS symptom reporting.

Results
=======

A total of 183 volunteers were ascertained within 6 weeks following EDI, 77 (42%) with subtype A and 106 (58%) with subtype C or D infection (Table [1](#T1){ref-type="table"}). Overall, approximately one-third of participants were female, with higher proportions of females among those with subtype C or D. Participants with subtype A were on average 3 years younger than participants with subtype C or D. Most volunteers with subtype A enrolled in Kigali or Kilifi (Table [1](#T1){ref-type="table"}), and most with subtype C enrolled in Lusaka or Copperbelt Province (Supplemental Table S1). Participants with subtype D enrolled only in Masaka, Kilifi, and Entebbe (Supplemental Table S1). Of those with known risk group status, persons with subtype A infections were evenly split between MSM and serodiscordant heterosexual couples, whereas most with subtype C or D infections were members of serodiscordant couples. Persons with subtype A infection were enrolled a few days earlier on average and had a slightly higher viral load than did persons with subtypes C or D.

###### 

Volunteer characteristics at enrolment^a^.

  Characteristic                                                                                                               Overall (*N* = 183)   Subtype A (*N* = 77)   Subtype C or D (*N* = 106)
  ---------------------------------------------------------------------------------------------------------------------------- --------------------- ---------------------- ----------------------------
  *N* (%) female                                                                                                               63 (34.4)             21 (27.3)              42 (39.6)
  Median (range) age[^b^](#TF1-2){ref-type="table-fn"}                                                                         29 (16--58)           27 (19--52)            30 (16--58)
  Site:[^b^](#TF1-2){ref-type="table-fn"}                                                                                                                                   
   Kigali                                                                                                                      33 (18.0)             29 (37.7)              4 (3.8)
   Masaka                                                                                                                      22 (12.0)             5 (6.5)                17 (16.0)
   Kilifi                                                                                                                      47 (25.7)             37 (48.0)              10 (9.4)
   Nairobi                                                                                                                     5 (2.7)               4 (5.2)                1 (1.0)
   Lusaka                                                                                                                      46 (25.1)             1 (1.3)                45 (42.5)
   Entebbe                                                                                                                     4 (2.2)               1 (1.3)                3 (2.8)
   Cape Town                                                                                                                   3 (1.7)               0 (0.0)                3 (2.8)
   Copperbelt                                                                                                                  17 (9.3)              0 (0.0)                17 (16.0)
   Rustenburg                                                                                                                  6 (3.3)               0 (0.0)                6 (5.7)
  Number (%) in risk group:[^b^](#TF1-2){ref-type="table-fn"}                                                                                                               
   Serodiscordant couples                                                                                                      120 (65.6)            36 (46.8)              84 (79.3)
   MSM                                                                                                                         45 (24.6)             35 (45.4)              10 (9.4)
   Other/don't know                                                                                                            18 (9.8)              6 (7.8)                12 (11.3)
  Median (interquartile range) days since EDI[^b^](#TF1-2){ref-type="table-fn"}                                                25 (19--33)           21 (18--32)            26 (21--33)
  Median (range) enrolment log~10~ viral load                                                                                  5.0 (1.4--7.3)        5.2 (1.4--7.3)         4.9 (2.6--7.0)
  Median (range) number of ARS[^c^](#TF1-3){ref-type="table-fn"} symptoms per participant [^b^](#TF1-2){ref-type="table-fn"}   3 (0, 11)             5 (0, 11)              2 (0,8)

ARS, acute retroviral syndrome; EDI, estimated date of HIV-1 infection.

^a^All within 42 days of estimated infection acquisition date.

^b^Subtype A vs. subtype C or D comparison statistically significant at α = 0.05.

^c^Acute retroviral syndrome.

Overall, 84.4% (95% confidence interval: 76.3--92.5%) of subtype A volunteers reported any ARS symptoms, compared with 60.4% (50.1--68.8%) of volunteers with subtypes C or D (Fig. [1](#F1){ref-type="fig"}). The median (range) number of symptoms per volunteer was 5 (0, 11) for subtype A, 2 (0, 8) for subtype C, and 1 (0, 8) for subtype D. In Kigali and Kilifi, the median was 4 (0, 8) and 7 (0, 11) among their 29 and 37 subtype A volunteers, respectively. The percentage of subtype A participants reporting each of the individual symptoms ranged from 6.5% (1.0--12.0%) for skin rash to 67.5% (57.1--78.0%) for fever, compared with a range of 6.6% (1.9--11.3%) for skin rash to 32.1% (23.2--41.0%) for headache among those with subtypes C or D. Each of the specific symptoms other than rash (unadjusted prevalence ratio = 0.98, 95% confidence interval: 0.32--2.98) was more prevalent in subtype A than in subtype C or D (combined), with the unadjusted prevalence ratio ranging from 1.94 (1.40, 2.70) for headache to 4.92 (2.24, 10.78) for lymphadenopathy. The corresponding prevalence ratio for reporting any symptoms was 1.40 (1.17, 1.68). Findings were similar but less precise in the sensitivity analysis restricted to Kilifi and Masaka volunteers (Supplemental Figure S2).

![Prevalence of acute retroviral syndrome symptoms by dichotomized HIV-1 subtype, all sites.](aids-31-2541-g001){#F1}

None of the 37 HLA types we examined was associated with ARS symptoms (results available on request), nor was calendar year of enrolment (*P* = 0.8), so we did not include HLA type or calendar time in our models. In both sets of multivariable models (with and without viral load), neither of the potential confounders (sex, time since enrolment) was selected for the final model. The total effect estimated in the final model was thus identical to the unadjusted prevalence ratio (1.40) above. The prevalence ratio arising from the final model with viral load included was 1.47 (1.20, 1.80). The similarity of this result to the estimate from the model without viral load suggests that the relationship between viral subtype and ARS symptoms is not mediated through viral load.

Discussion
==========

ARS symptoms were more prevalent in patients infected with HIV-1 subtype A vs. subtype C or D in our multicentre cohort in Africa, a difference that was independent of viral load \[[@R6]\], HLA type, sex, and time of enrolment. These findings, from the largest study of ARS symptoms by HIV-1 subtype to date, may help to explain differences in ARS reporting across previous studies from different regions of sSA. Indeed, the greater number of symptoms per participant that we observed (overall median of 3) vs. that of the recent study of Robb *et al.*\[[@R9]\] (median = 1) may be partially explained by differences in cohort composition according to subtype \[[@R23]\].

Although it is unknown whether subtype-specific viral properties or immune activation cause AHI symptoms, observed symptom differences by HIV-1 subtype have public health significance. Patients with symptomatic AHI frequently seek healthcare \[[@R24]--[@R26]\], presenting opportunities for diagnosis and immediate treatment. Unfortunately, guidance is lacking on who should be evaluated for AHI in sSA \[[@R5],[@R27]\], but we previously showed that screening at-risk adults for AHI using a simple algorithm based on seven characteristics would substantially reduce the number of HIV-1-seronegative patients requiring testing \[[@R27]\]. The yield of this algorithm and impact of RNA testing (compared with standard HIV testing) will be assessed among 2875 adults seeking urgent care for symptoms in a proof-of-concept trial in Kenya (R01 AI124968--01A1).

We note that there may have been some subtype misclassification because of our reliance on the *POL* region, and that our insights exclude recombinant subtypes \[[@R28]\] and subtypes other than A, C, or D. Additionally, although most infections in discordant couples were caused by a single strain \[[@R29]\], approximately a third of MSM in Kenya had multiple strains at infection \[[@R30]\], some of which may have been obscured in analyses. Finally, we note that our enrolment viral load was likely a 'postpeak' measurement, and the extent to which the relationship between this measure and peak viral load is consistent across subtypes will determine the extent to which our estimated direct effect of subtype reflects the effect not mediated through peak viral load.

Despite these limitations, the differences that we observed in ARS symptoms across HIV-1 subtypes suggest that further investigation of viral characteristics causing immune activation and control is necessary \[[@R23]\]. As studies in East Africa \[[@R9]\] and South Africa \[[@R31]\] demonstrate that median peak viral loads are very high, corresponding with high transmissibility, further research on the yield of symptom-based AHI screening algorithms in different regions of sSA is needed.
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